Brian Goff - Jul 14, 2021 Form 4 Insider Report for ALEXION PHARMACEUTICALS, INC. (ALXN)

Role
EVP & Chief Commercial Officer
Signature
/s/ Douglas Barry, Attorney-in-Fact for Brian Goff
Stock symbol
ALXN
Transactions as of
Jul 14, 2021
Transactions value $
$0
Form type
4
Date filed
7/16/2021, 04:43 PM
Previous filing
Jun 9, 2021
Next filing
Jul 23, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALXN Common Stock, par value $.0001 per share Award $0 +30.6K +33.79% $0.00 121K Jul 14, 2021 Direct F1
transaction ALXN Common Stock, par value $.0001 per share Award $0 +29.5K +24.31% $0.00 151K Jul 14, 2021 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2019 under the 2017 Stock Incentive Plan.
F2 On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2020 under the 2017 Stock Incentive Plan.